ATTR-cardiac amyloidosis (ATTR-CM) is a serious heart condition that often goes unnoticed, particularly within Black communities. Recognizing this critical gap, BlackDoctor, in partnership with BridgeBio Pharma, hosted an insightful discussion titled ‘Understanding ATTR-CM: A Powerful Conversation.’ The event brought together leading cardiologists, medical experts, and a patient advocate to shed light on the science, personal experiences, and crucial importance of early detection and treatment for this condition.
What is ATTR-CM and Why It Matters
ATTR-CM develops when unstable transthyretin (TTR) proteins fragment and form amyloid deposits in the heart muscle. This can lead to debilitating symptoms such as fatigue, shortness of breath, irregular heart rhythms, and ultimately, heart failure. Despite its severity, ATTR-CM is frequently underdiagnosed because its symptoms can be mistaken for normal aging or other common health issues. This lack of awareness among both patients and healthcare providers often results in misdiagnoses and delayed treatment.
The need for education, advocacy, and culturally sensitive care is especially pronounced for Black patients, who may face unique genetic risk factors and systemic healthcare disparities. Early detection and treatment are key to improving health-related quality of life for those affected.
Advances in Treatment and Support
The discussion highlighted that significant advancements in treatment are available. Therapies like Attruby® (acoramidis), a TTR protein stabilizer, have shown promise in reducing death and hospitalizations related to heart problems in adults with ATTR-CM. Beyond medication, patient support programs and copay assistance are vital for helping families manage the financial burdens of long-term treatment.
Medical experts stressed the importance of early identification. Effective management is most successful when ATTR-CM is diagnosed before extensive heart damage occurs. This involves actively listening to patient symptoms, considering family medical history, and utilizing genetic testing when appropriate.
Expert Panel Insights
The session featured valuable perspectives from a diverse group of professionals:
- Dr. Ashanti Carter (Chief Academic Liaison, BlackDoctor) served as the moderator.
- Dr. Barbara Hutchinson, MD, PhD, FACC (Cardiologist, Chesapeake Cardiac Care), provided medical expertise.
- Dr. Ola Akinboboye, MD, MPH, MBA (Medical Director, Laurelton Heart Specialists), shared clinical insights.
- Velma Henderson, a caregiver advocate, offered a crucial lived experience perspective on navigating ATTR-CM within a family.
Key Takeaways for Patients
The conversation offered actionable advice for patients, particularly those in the Black community:
- Know the Symptoms: Persistent fatigue, swelling, and shortness of breath should prompt a conversation with a doctor, as they may indicate ATTR-CM.
- Ask About ATTR-CM: Patients experiencing heart-related symptoms should proactively discuss ATTR-CM with their healthcare providers.
- Family Matters: Given the 50% chance of inheriting hereditary ATTR-CM, family testing is essential.
- Treatment Options Exist: While not curable, medications can help manage symptoms, reduce hospitalizations, and improve quality of life.
- Advocate for Yourself: Patients and caregivers are encouraged to seek answers, obtain second opinions, and find providers knowledgeable about ATTR-CM.
The discussion also included important safety information about Attruby®, its uses, potential side effects, and the importance of consulting a healthcare provider. Information on clinical trials and other resources was also shared, emphasizing the ongoing efforts to advance research and improve patient outcomes.
If you or a loved one are experiencing persistent heart-related symptoms, don’t dismiss them. Talk to your doctor about ATTR-CM and explore the available resources. What are your thoughts on the importance of raising awareness for conditions like ATTR-CM? Share your perspective in the comments below!